clinical trial · NCT07290062
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Insmed Gene Therapy LLC·phase1·recruiting·n = 23
Amyotrophic Lateral SclerosisINS1202
brief summary
The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \<80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genetic mutation.
started
Jan 9, 2026
primary completion
Mar 31, 2030
completion
Mar 31, 2030
last updated
Apr 29, 2026
official title
A Phase 1, Multicenter, Open-label, Dose-Finding Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection of INS1202 in Patients With Amyotrophic Lateral Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol